Larotrectinib Inches Closer to FDA Approval for TRK+ Cancers
Anna Farago, MD, PhD, discusses the biology of larotrectinib, as well as the importance of genetic testing for molecular alterations like TRK in patients with locally advanced solid tumors.
Source: OncLive